The company posted a multifold jump per cent in consolidated net profit to Rs 230 crore as compared to Rs 46 crore a year ago ...

Ovarian cancer continues to pose a significant challenge in the medical field, remaining one of the leading causes of death ...

GlaxoSmithKline Pharmaceuticals shares surged 20% to ₹2,421.30 after a strong Q3FY25 performance, reporting a 400% rise in ...

Their prescription medicines range across therapeutic ... This follows a global transaction between GlaxoSmithKline plc, UK (GSK) and Novartis AG, Switzerland (Novartis) which was completed ...

It also develops medicines for various indications that ... AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was ...

The global APOL1-mediated kidney disease market is poised for substantial expansion, with projections indicating a remarkable ...